Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EH domain-containing protein 4 (EHD4) is a member of the dynamin-related ATPase family involved in cellular membrane trafficking, endocytic recycling, and membrane remodeling in multiple tissues[2][3][4][6][7]. EHD4 binds ATP and associates with lipid membranes, oligomerizing and inducing membrane tubulation to facilitate early endosomal transport[2][4]. In neuronal cells, EHD4 is implicated in the internalization of neurotrophic receptors (TrkA, TrkB) and interacts with proteins such as EHD1, NUMB, PACSIN2, and MICALL1 in the control of membrane protein trafficking[6]. EHD4 is expressed in various tissues, prevalent in heart and detectable in brain, fibroblasts, and cartilage, with functional redundancy alongside other EHD family members[1][6][7]. Disease associations include several cancers and developmental abnormalities[3][6]. No drugs are currently clinically known to directly target EHD4.
Drugs targeting EHD4 would likely modulate endocytic trafficking, membrane remodeling, or receptor internalization pathways; however, no specific drugs are known[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on EH domain-containing protein 4 (EHD4).